Tamoxifen for breast cancer among hysterectomised women

U Veronesi, P Maisonneuve, V Sacchini, N Rotmensz… - The Lancet, 2002 - thelancet.com
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials
have not been consistent. In our extended follow-up (median 81· 2 months, IQR 66· 0–87· 2) …
被引用次数：209 相关文章

Tamoxifen for breast cancer among hysterectomised women

U Veronesi, P Maisonneuve, V Sacchini, N Rotmensz… - The Lancet, 2002 - Elsevier
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials
have not been consistent. In our extended follow-up (median 81· 2 months, IQR 66· 0–87· 2) …

Tamoxifen for breast cancer among hysterectomised women

U Veronesi, P Maisonneuve, V Sacchini, N Rotmensz… - The Lancet, 2002 - thelancet.com
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials
have not been consistent. In our extended follow-up (median 81· 2 months, IQR 66· 0–87· 2) …

Tamoxifen for breast cancer among hysterectomised women.

U Veronesi, P Maisonneuve, V Sacchini… - Lancet (London …, 2002 - europepmc.org
Tamoxifen for breast cancer among hysterectomised women. - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …

Tamoxifen for Breast cancer among Hysterectomised women.

U Veronesi, P Maissoneuve, V Sacchini, N Rotmensz… - THE LANCET, 2002 - iris.uniroma1.it
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials
have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of …

Tamoxifen for breast cancer among hysterectomised women

U Veronesi, P Maisonneuve… - Lancet (London …, 2002 - pubmed.ncbi.nlm.nih.gov
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials
have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of …

Tamoxifen for breast cancer among hysterectomised women

U Veronesi, P Maisonneuve, V Sacchini, N Rotmensz… - The Lancet, 2002 - infona.pl
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials
have not been consistent. In our extended follow-up (median 81· 2 months, IQR 66· 0–87· 2) …

[引用][C] Tamoxifen for breast cancer among hysterectomised women

U VERONESI, P MAISONNEUVE… - Lancet (British …, 2002 - pascal-francis.inist.fr
Tamoxifen for breast cancer among hysterectomised women CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search …

Tamoxifen for breast cancer among hysterectomised women.

U Veronesi, P Maisonneuve, V Sacchini - The Lancet, 2002 - elibrary.ru
Presents an extended follow-up of the Italian Randomised Trial of Tamoxifen among
Hysterectomised Women. Finding that the drug did not significantly protect against breast …

[引用][C] Tamoxifen for breast cancer among hysterectomised women

U Veronesi, P Maisonneuve, V Sacchini, N Rotmensz - The …, 2002 - Elsevier Limited